Table 2 Clinical and biological variables during the normothermic phase of TTM, according to outcomes
From: Cerebral autoregulation in anoxic brain injury patients treated with targeted temperature management
|  | Survivors (n = 19) | Non-survivors (n = 31) | p value | FO (n = 14) | UO (n = 36) | p value | |
|---|---|---|---|---|---|---|---|
Sedatives, n (%) | 6 (31) | 19 (61) | 0.08 | 4 (29) | 21 (58) | 0.11 | |
NMBA, n (%) | 1 (5) | 7 (23) | 0.13 | 1 (7) | 7 (19) | 0.41 | |
Mechanical ventilation, n (%) | 8 (42) | 26 (84) | < 0.01 | 3 (21) | 31 (86) | < 0.01 | |
MAP, mmHg | 77 [70–89] | 75 [70–83] | 0.47 | 81 [70–91] | 75 [70–85] | 0.37 | |
Heart rate, bpm | 91 [68–111] | 88 [78–103] | 0.82 | 93 [66–108] | 88 [78–106] | 0.65 | |
Temperature, °C | 37.0 [36.8–37.4] | 36.8 [36.4–37.1] | 0.08 | 37.1 [37.0–37.5] | 36.8 [36.5–37.1] | 0.04 | |
Hemoglobin, g/dL | 12.2 [10.7–14.0] | 10.8 [8.9–12.8] | 0.17 | 11.9 [10.5–14.0] | 11.5 [9.3–13.7] | 0.68 | |
PEEP, cmH2O | 5 [5–8] | 6 [5–10] | 0.46 | 5 [5–9] | 6 [5–10] | 0.51 | |
FiO2 | 0.4 [0.3–0.5] | 0.3 [0.3–0.5] | 0.16 | 0.4 [0.3–0.5] | 0.3 [0.3–0.5] | 0.25 | |
pH | 7.36 [7.32–7.39] | 7.40 [7.35–7.42] | 0.20 | 7.38 [7.34–7.39] | 7.4 [7.33–7.42] | 0.88 | |
PaCO2, mmHg | 39 [37–40] | 36 [34–40] | 0.02 | 39 [37–42] | 37 [34–40] | 0.07 | |
PaO2, mmHg | 83 [70–92] | 80 [72–91] | 0.74 | 85 [76–94] | 80 [71–91] | 0.43 | |
ScvO2, % | 75 [72–79] | 75 [73–78] | 0.82 | 75 [72–79] | 75 [72–78] | 0.83 | |
Lactate, mmol/L | 1.3 [1.0–2.0] | 1.3 [1.0–2.3] | 0.66 | 1.3 [1.0–1.7] | 1.3 [1.0–2.4] | 0.37 | |
Time to TCD assessment, hours | 38 [35–43] | 38 [36–46] | 0.78 | 39 [36–42] | 38 [32–48] | 0.98 | |
Cardio-active medications, n (%) | 9 (47) | 23 (74) | 0.07 | 6 (43) | 26 (72) | 0.10 | |